Protalix BioTherapeutics GAAP EPS of -$0.05 misses by $0.13, revenue of $10.11M misses by $11.49M
Source: SeekingAlpha
2025-05-09 06:56:32 ET
More on Protalix BioTherapeutics
- Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline
- Protalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call Transcript
- Protalix BioTherapeutics Q1 Earnings Preview
- Protalix plans Phase 2 for PRX-115 in H2 2025, projects higher royalty revenues by 2030
- Seeking Alpha’s Quant Rating on Protalix BioTherapeutics
Read the full article on Seeking Alpha
For further details see:
Protalix BioTherapeutics GAAP EPS of -$0.05 misses by $0.13, revenue of $10.11M misses by $11.49M
Protalix BioTherapeutics Inc.
NASDAQ: PLX
PLX Trading
-2.95% G/L:
$2.80 Last:
326,063 Volume:
$2.82 Open:
PLX Latest News
March 11, 2026 06:50:00 am
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
March 09, 2026 06:00:00 am
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
PLX Stock Data
$215,126,659
70,448,955
0.23%
25
N/A
Biotechnology & Life Sciences
Healthcare
US
Hackensack
